Modifications to the “Classical” Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis: A Less Toxic Approach is Feasible and Improves the Neurological Condition. A Mexican Perspective
Sign Up to like & getrecommendations! Published in 2018 at "Biology of Blood and Marrow Transplantation"
DOI: 10.1016/j.bbmt.2017.12.067
Abstract: ered as an ordinal variable (better, stable, worse) due to the lack of standardized response assessment. Results: For the 33 patients included in the analysis, median age was 55 years, and 21(64%) males. Seventeen patients… read more here.
Keywords: response; line; modifications classical; later line ... See more keywords
Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of gastroenterology and hepatology"
DOI: 10.1111/jgh.16225
Abstract: BACKGROUND AND AIM The study goal was to compare the outcomes of patients with unresectable hepatocellular carcinoma (HCC) who received atezolizumab plus bevacizumab (Atezo/Bev) as either first- or later-line systemic therapy. METHODS A total of… read more here.
Keywords: later line; line systemic; first line; therapy ... See more keywords
A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic adenocarcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359221119539
Abstract: Background: Nanoliposomal encapsulation of irinotecan (nal-IRI) with 5-fluorouracil and leucovorin (5-FU/LV) has shown a survival benefit for gemcitabine-pretreated patients with metastatic pancreatic adenocarcinoma (mPAC). The aim of this study was to evaluate the effectiveness and… read more here.
Keywords: later line; oncology; nal iri; iri plus ... See more keywords
Real-world clinical outcomes of nivolumab and taxane as a second- or later-line therapy for recurrent or unresectable advanced esophageal squamous cell carcinoma
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2023.1126536
Abstract: Background Nivolumab is approved in Japan as a second-line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC) resistant to fluoropyrimidine and platinum-based drugs. It is also used in adjuvant and primary postoperative therapies.… read more here.
Keywords: later line; second later; line therapy; line ... See more keywords
Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14205095
Abstract: Simple Summary Osimertinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) designed to overcome acquired T790M resistance mutations in non-small cell lung cancer (NSCLC). A total of 172 patients with advanced NSCLC… read more here.
Keywords: later line; t790m mutation; t790m; acquired t790m ... See more keywords